Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anixa Biosciences

3.23
+0.04001.25%
Post-market: 3.300.0700+2.17%15:57 EDT
Volume:38.26K
Turnover:123.37K
Market Cap:104.04M
PE:-8.56
High:3.39
Open:3.19
Low:3.19
Close:3.19
Loading ...

Anixa Biosciences Receives Notice of Allowance From U.S. Patent and Trademark Office for Patent Covering Breast Cancer Vaccine Technology

THOMSON REUTERS
·
09 Apr

Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for Patent Covering Breast Cancer Vaccine Technology

PR Newswire
·
09 Apr

EXCLUSIVE: Anixa Biosciences Receives Key US Patent Nod For Breast Cancer Vaccine Patent

Benzinga
·
09 Apr

Anixa Biosciences Is Maintained at Buy by D. Boral Capital

Dow Jones
·
26 Mar

Anixa Enters Letter of Intent to Develop Verdi's AI-Guided Cancer Vaccines

MT Newswires Live
·
25 Mar

BRIEF-Anixa Biosciences Enters Letter of Intent with VERDI Solutions to Develop Artificial Intelligence-Guided Personalized and Off-the-Shelf Cancer Vaccines

Reuters
·
25 Mar

Anixa Biosciences Enters Letter of Intent With Verdi Solutions to Develop Artificial Intelligence-Guided Personalized and off-the-Shelf Cancer Vaccines

THOMSON REUTERS
·
25 Mar

EXCLUSIVE: Anixa Biosciences Inks Letter of Intent with Austria-Based VERDI Solutions To Develop AI-Guided Personalized Cancer Vaccines

Benzinga
·
25 Mar

Anixa Biosciences Price Target Maintained With a $7.00/Share by HC Wainwright & Co.

Dow Jones
·
25 Mar

Anixa Biosciences: Buy Rating Affirmed Amid Patent Approval and Clinical Trial Advancements

TIPRANKS
·
25 Mar

Anixa Biosciences Receives US Patent Notice of Allowance for Potential Ovarian Cancer Vaccine

MT Newswires Live
·
24 Mar

BRIEF-Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine

Reuters
·
24 Mar

Anixa Biosciences Receives Notice of Allowance From Uspto for Ovarian Cancer Vaccine

THOMSON REUTERS
·
24 Mar

Anixa Biosciences Holds Annual Stockholder Meeting 2025

TIPRANKS
·
22 Mar

Anixa Biosciences Initiated at Buy by Maxim Group

Dow Jones
·
21 Mar

Anixa Biosciences CEO to Present at the 2025 CAGLA NeauxCancer Conference on March 28th

PR Newswire
·
17 Mar

BEAM Down Despite Positive Initial Data From Genetic Disorder Study

Zacks
·
12 Mar

Is Gilead Sciences (GILD) Stock Outpacing Its Medical Peers This Year?

Zacks
·
10 Mar

Anixa Biosciences 2025 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties

PR Newswire
·
10 Mar

Anixa Biosciences Announces Chief Development Officer DR. PAM Garzone to Speak at the Alliance for Cancer Gene Therapy Summit 2025 on March 19TH

THOMSON REUTERS
·
03 Mar